[Mutational analysis of KRAS prior to targeted therapy in colorectal cancer. Quality control of molecular pathological methods in Sweden].
Enlund
Fredrik
F
Klinisk molekylär patologi, verksamheten för patologi och cytologi, Sahlgrenska universitetssjukhuset, Göteborg. fredrik.enlund@gu.se
Helenius
Gisela
G
Palmqvist
Richard
R
Edsjö
Anders
A
Sundström
Magnus
M
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000235:genetics*; D004252:DNA Mutational Analysis; D066246:ErbB Receptors / Q000187:drug effects / Q000502:physiology; D011905:Genes, ras / Q000235:genetics*; D005820:Genetic Testing / Q000379:methods / Q000592:standards; D006801:Humans; D009154:Mutation / Q000235:genetics; D016133:Polymerase Chain Reaction; D057285:Precision Medicine; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D016283:Proto-Oncogene Proteins p21(ras); D011785:Quality Assurance, Health Care; D017422:Sequence Analysis, DNA; D018631:ras Proteins / Q000235:genetics*
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; C117307:KRAS protein, human; D011518:Proto-Oncogene Proteins; D066246:ErbB Receptors; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins
Mutationsanalys av KRAS inför riktad terapi vid kolorektalcancer. Kvalitetskontroll av molekylärpatologiska metoder i Sverige.